U.S. President Donald Trump told reporters on Tuesday that his expected meeting with Chinese President Xi Jinping may not take place as planned, even though it was scheduled to happen in about two weeks during the Asia-Pacific Economic Cooperation summit in South Korea. Speaking from the White House Rose Garden during a lunch with Republican […]U.S. President Donald Trump told reporters on Tuesday that his expected meeting with Chinese President Xi Jinping may not take place as planned, even though it was scheduled to happen in about two weeks during the Asia-Pacific Economic Cooperation summit in South Korea. Speaking from the White House Rose Garden during a lunch with Republican […]

Trump said his planned meeting with Xi Jinping might not happen

2025/10/22 04:10

U.S. President Donald Trump told reporters on Tuesday that his expected meeting with Chinese President Xi Jinping may not take place as planned, even though it was scheduled to happen in about two weeks during the Asia-Pacific Economic Cooperation summit in South Korea.

Speaking from the White House Rose Garden during a lunch with Republican lawmakers, Trump said he believes the meeting could result in a strong agreement on trade but admitted that “maybe it won’t happen.”

“I have a great relationship with President Xi. I expect to be able to make a good deal with him,” Trump said, adding, “I want him to make a good deal for China — but it’s got to be fair.” He said he views the possible sit-down as “very successful” but didn’t rule out the chance of it falling apart completely.

“Maybe somebody will say, ‘I don’t want to meet, it’s too nasty.’ But it’s really not nasty. It’s just business,” Trump added.

Trump pushes for deal, but trade fight with China escalates

Trump confirmed that the date and time for the meeting haven’t been finalized but said he expects it will happen “in about two weeks.”He also made it clear that the U.S. will continue pushing for changes in the trade relationship, regardless of whether or not the meeting with Xi takes place.

The agenda for that potential conversation is expected to include fentanyl, soybean exports, Taiwan, and the current fight over rare earth materials, which has escalated sharply in recent weeks.

Ahead of the expected Trump-Xi meeting, Treasury Secretary Scott Bessent is set to meet with Chinese counterparts this weekend. The plan is to work on reducing tensions after China rolled out new restrictions on rare earth exports and Trump responded by threatening more tariffs on Chinese products. This back-and-forth has added to the uncertainty around the summit and what could come out of it.

On Monday, just a day before making the remarks about Xi, Trump met with Australian Prime Minister Anthony Albanese at the White House. Both leaders signed a new agreement to team up on developing supply chains for rare earths and critical minerals.

That move directly challenges China, the world’s biggest supplier of rare earths, and came right after Beijing’s announcement that it would tighten controls on those materials. That decision by China was made earlier this month.

China fires back after U.S.-Australia deal

Following the U.S.-Australia agreement, the Chinese government issued a response. Liu Pengyu, a spokesperson for the Chinese Embassy, told FOX Business that “the global industrial and supply chains came into shape as a result of the choices of the market and businesses.”

Liu said countries with mineral resources “need to play a positive role in keeping relevant industrial and supply chains safe and stable and to ensure normal trade and economic cooperation.”

As the two governments throw punches over trade, minerals, and tech control, the numbers paint a clear picture of who holds the upper hand — and who’s trying to catch up.

Data from the U.S. Geological Survey shows that in 2024, China produced 270,000 tons of rare earths and holds 44 million tons in reserves. The U.S. only produced 45,000 tons, with 1.9 million tons in reserves. Australia trails with 13,000 tons produced and 5.7 million tons of reserves.

The reason this matters? Rare earths power everything from smartphones and electric vehicle batteries to military equipment like radars and cruise missiles. With Trump still unsure if he’ll meet Xi in South Korea, the weight of the global tech economy, and a whole lot of geopolitics, is now hanging on whether the two presidents can agree to talk.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share